New pilot study aims to personalize glioma treatment with drug cocktails

NCT ID NCT07025226

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This early-phase trial at Mayo Clinic is testing combinations of four drugs (dasatinib, quercetin, fisetin, and temozolomide) in 30 adults with previously treated glioma that still has residual tumor cells. The goal is to see if it's feasible to use individual patient data from blood, spinal fluid, and scans to guide which drug combination to use next. The study focuses on safety and turnaround time for test results, not yet on curing the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dasatinib, quercetin, fisetin, and temozolomide
What this could lead to
If successful, this could point toward a way to personalize treatment for glioma patients with leftover tumor cells after standard therapy.
What could go wrong
This is a very early (Phase 1) pilot study with only 30 participants. It primarily tests feasibility and safety, not effectiveness. The drug combinations may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.